Rising Incidences of Metabolic Disorders Is Driving the North American Metabolic Disorder Therapeutics Market

North American metabolic disorder therapeutics market is estimated to grow at a CAGR of 7.6% during the forecast period. Growing incidences of metabolic disorders are encouraging the growth of the market. An increasing prevalence of diabetes and obesity have been witnessed in the region owing to the sedentary lifestyle habits. As per the World Health Organization (WHO), since 1975, global obesity has nearly tripled. In 2016, over 1.9 million adults, aged 18 years and more were overweight and among these, 650 million were obese. In 2016, 39% of adults aged 18 years and more were overweight and 13% were obese. A sedentary lifestyle is a major factor for the rising incidence of metabolic syndrome in the region, characterized by low nutrient-dense, foods, and physical inactivity. During the early period of life, this exposure is most potent leads to childhood obesity which is a key risk factor for metabolic syndrome in adults. Rimonabant (Acomplia), dexfenfluramine (Redux), orlistat (Xenical), and sibutramine (Meridia, Reductil), have been registered to treat obesity. More drugs are in clinical trials for metabolic disorders treatment, which is expected to offer a potential scope for market growth. 

Browse the full report description North American Metabolic Disorder Therapeutics Market Size, Share & Trends Analysis Report, By Therapy (Drug Therapy, Gene Therapy, Cellular Transplantation, Enzyme Replacement Therapy, and Others), By Disease (Obesity, Diabetes, Lysosomal Storage Disease, Hypercholesterolemia, and Others) and Forecast, 2020-2026 at https://www.omrglobal.com/industry-reports/north-american-metabolic-disorder-therapeutics-market

Scope of the North American Metabolic Disorder Therapeutics Market

Market Coverage

• The market number available for 2019-2026
• Base year- 2019
• Forecast period- 2020-2026
• Segment Covered- By Therapy and Disease
• Countries Covered- US and Canada
• Competitive Landscape- AbbVie, Inc., Alexion Pharmaceuticals, Inc., Pfizer Inc., Eli Lilly & Co., and AstraZeneca plc

Recent Strategic Initiatives in the North American Metabolic Disorder Therapeutics Market

• In June 2020, Ultragenyx declared the US FDA approval of Dojolvi (triheptanoin). It is a source of fatty acids and calories to treat pediatric and adult patients suffering from long-chain fatty acid oxidation disorders (LC-FAOD). Dojolvi is a synthetic, highly purified, and 7-carbon fatty acid triglyceride particularly aimed to offer medium-chain, odd-carbon fatty acids as an energy source and metabolite replacement for people suffering from LC-FAOD. 
• In March 2020, Eli Lilly and Co. declared the global licensing and research partnership with Sitryx, a biopharmaceutical company engaged in the development of therapeutics in immuno-inflammation and immuno-oncology. Under the partnership, the companies will study up to four new preclinical targets that are found by Sitryx that could result in potential new medicines for autoimmune diseases. Lilly will make a $10 million equity investment in Sitryx and Sitryx will get an upfront payment of $50 million.

Key questions addressed by the report

• What is the market growth rate?
• Which segment dominates the market in the base year?
• Which segment will project the fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from the pre-COVID-19 forecast

o Most affected region/segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

North American Metabolic Disorder Therapeutics Market-Segmentation

By Therapy

• Drug Therapy
• Gene Therapy
• Cellular Transplantation
• Enzyme Replacement Therapy
• Others

By Disease

• Obesity
• Diabetes
• Lysosomal Storage Disease
• Hypercholesterolemia
• Others

North American Metabolic Disorder Therapeutics Market– Segment by Country

• US
• Canada